GlassScriptPhysician profile
Howard J Lee
NPI 1427097948
$6,225.32
in general payments reported to CMS, 2019-2025
36 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,589 · 2020: $1,214 · 2021: $230 · 2022: $205 · 2023: $444 · 2024: $936 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,907 · Education: $79.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,907.13 |
| Education | $79.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,138.94 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $802.05 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Inspire Medical Systems, INC. | $540.44 | 2020-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $445.56 | 2019-2025 | |
| Insmed, INC. | $428.31 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $414.16 | 2019-2025 | |
| Harmony Biosciences LLC | $294.86 | 2020-2025 | Wakix |
| Verona Pharma, INC. | $213.45 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $209.39 | 2019-2025 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $198.37 | 2024-2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $186.58 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $147.91 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $132.39 | 2019-2023 | Uptravi, Opsumit |
| Electromed, INC. | $128.88 | 2024-2025 | Smartvest |
| Csl Behring | $122.73 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $116.99 | 2022-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $104.83 | 2019-2025 | Dupixent |
| Pulmonx Corporation | $75.72 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| United Therapeutics Corporation | $71.47 | 2024-2025 | Tyvaso, Tyvaso |
| Amgen INC. | $64.84 | 2024-2025 | Tezspire |
| Resmed Corp | $53.62 | 2019-2023 | |
| Grifols USA, LLC | $51.59 | 2020-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $32.66 | 2025 | Sunosi |
| Circassia INC. | $30.08 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.32 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.02 | 2019 | |
| Vifor Pharma, INC. | $21.22 | 2024 | Zemaira |
| Pfizer INC. | $19.14 | 2025 | |
| Shire North American Group INC | $16.99 | 2019 | |
| Mylan Specialty L.P. | $16.89 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.81 | 2024 | Quviviq |
| Kaleo, INC. | $15.34 | 2019 | |
| Lilly USA, LLC | $15.34 | 2025 | Zepbound |
| Eisai INC. | $13.04 | 2020 | |
| Advanced Respiratory, INC | $11.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.